-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Neurocrine Biosciences Inc quarterly/annual Income Tax Expense (Benefit) history and growth rate from Q1 2019 to Q2 2024.
- Neurocrine Biosciences Inc Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $33.6M, a 28.7% increase year-over-year.
- Neurocrine Biosciences Inc Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was $108M, a 86.7% increase year-over-year.
- Neurocrine Biosciences Inc annual Income Tax Expense (Benefit) for 2023 was $82.4M, a 38.7% increase from 2022.
- Neurocrine Biosciences Inc annual Income Tax Expense (Benefit) for 2022 was $59.4M, a 403% increase from 2021.
- Neurocrine Biosciences Inc annual Income Tax Expense (Benefit) for 2021 was $11.8M.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)